In a significant announcement, the International Gaucher Alliance (IGA) is commemorating its 30th anniversary by unveiling a strategic five-year plan, reaffirming its commitment as a global advocate for Gaucher patients and their families. Concurrently, this month also marks the observance of Rare Disease Day, shedding light on the challenges faced by individuals with rare medical conditions such as Gaucher disease.
Gaucher disease, a rare genetic disorder, is identified by an insufficiency of the enzyme glucocerebrosidase, resulting in harmful lipid buildup. Typical symptoms include hepatosplenomegaly, thrombocytopenia, anaemia, and skeletal complications. These presentations diverge among the disease classifications: type 1, type 2, and type 3.
In recognition of its 30th anniversary, the IGA unveiled a visionary five-year strategic plan extending to 2029. Originating in Trieste, Italy, in 1994, the organisation now embarks on a pivotal journey to reinforce its global impact and advocacy for Gaucher patients. This newly announced strategic blueprint is testament to the IGA’s enduring commitment to fostering awareness, advancing treatment accessibility, and enhancing support services for individuals affected by Gaucher disease worldwide. Throughout 2024, a series of events will commemorate this milestone, inviting patients and their families to reflect on the transformative journey of the IGA and the evolving landscape of Gaucher advocacy over the past three decades.
The first ‘imperative’ of the IGA’s strategy plan is to enhance Gaucher patient access to diagnosis, treatment, and care. This involves creating online resources on the IGA website to pinpoint diagnostic centres worldwide. Additionally, a roadmap of diagnostic pathways in Africa will be developed to ensure sustainable diagnostic services tailored to each region/country. Moreover, efforts will be made to educate doctors on signs and symptoms through collaborations with various organisations. The IGA aims to further promote guidelines set out by the International Working Group on Gaucher Disease (IWGGD) in regional manager programs to share best practices and ensure optimal patient care.
A critical aspect of the strategy involves rolling out an awareness campaign called “Gaucher red flags” to alert clinicians to key signs and symptoms. Collaboration with healthcare professionals in various fields, including haematology and oncology, will ensure global coverage. This multifaceted approach aims to improve the timeliness and accuracy of Gaucher disease diagnosis.
The second strategic imperative focuses on influencing the Gaucher disease research agenda to address unmet needs. This entails early engagement with pharmaceutical companies, educating them about the disease’s impact from patient and caregiver perspectives. Encouraging companies to engage with regulators early in drug development ensures patient voices are heard in discussions. Importantly, the promotion of clinical trial sites in underserved countries is part of this goal, ensuring ethical considerations are prioritised. By actively involving the IGA in discussions and advocating for accessible treatment, the organisation aims to steer research towards addressing critical patient needs.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The final strategic imperative centres on empowering and supporting IGA members and the wider Gaucher community worldwide. This involves exploring the development of regional hub networks to overcome language and time zone barriers. The IGA aims to further strengthen governance structures and expand volunteer programs to enhance the organisation’s capacity to deliver projects effectively.
Additionally, the IGA aims to achieve this final goal by ensuring consistent translation of main documents into different languages and providing simultaneous interpretation for webinars to ensure accessibility and inclusivity. The IGA stated it seeks to increase regional manager programs in countries lacking formal structures and aims to improve education, disease awareness, and treatment access for Gaucher patients. Through these initiatives, the IGA seeks to bolster advocacy efforts and support for the global Gaucher community.
The unveiling of the IGA’s strategic plans aligns with Rare Diseases Day on February 29, a global platform dedicated to raising awareness and advocating for the approximately 300 million individuals worldwide affected by rare diseases, including Gaucher disease. This synchrony underscores the critical importance of concerted efforts to enhance understanding, support, and resources for rare disease communities. Looking forward, the IGA remains steadfast in its commitment to driving tangible improvements in outcomes for Gaucher patients through continued advocacy, collaboration, and innovation in the field of rare diseases.